Cargando…

Investigation of anti-galectin-8 levels in patients with multiple sclerosis: A consort-clinical study

Galectins are a family of endogenous mammalian lectins involved in pathogen recognition, killing, and facilitating the entry of microbial pathogens and parasites into the host. They are the intermediators that decipher glycan-containing information about the host immune cells and microbial structure...

Descripción completa

Detalles Bibliográficos
Autores principales: Cinkir, Ufuk, Bir, Levent Sinan, Tekin, Selma, Karagulmez, Ahmet Magrur, Avci Cicek, Esin, Senol, Hande
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9829274/
https://www.ncbi.nlm.nih.gov/pubmed/36607856
http://dx.doi.org/10.1097/MD.0000000000032621
_version_ 1784867435013210112
author Cinkir, Ufuk
Bir, Levent Sinan
Tekin, Selma
Karagulmez, Ahmet Magrur
Avci Cicek, Esin
Senol, Hande
author_facet Cinkir, Ufuk
Bir, Levent Sinan
Tekin, Selma
Karagulmez, Ahmet Magrur
Avci Cicek, Esin
Senol, Hande
author_sort Cinkir, Ufuk
collection PubMed
description Galectins are a family of endogenous mammalian lectins involved in pathogen recognition, killing, and facilitating the entry of microbial pathogens and parasites into the host. They are the intermediators that decipher glycan-containing information about the host immune cells and microbial structures to modulate signaling events that cause cellular proliferation, chemotaxis, cytokine secretion, and cell-to-cell communication. They have subgroups that take place in different roles in the immune system. The effect of galectin-8 on multiple sclerosis disease (MS) has been studied in the literature, but the results seemed unclear. In this study, we aimed to determine anti-galectin-8 (anti-Gal-8) levels in MS and their potential use as biomarkers. METHODS: In this experimental study, 45 MS patients diagnosed according to McDonald criteria were included in the patient group. The healthy control group contained 45 people without MS diagnosis and any risk factors. Demographic data, height, weight, body mass index, blood glucose, thyroid-stimulating hormone, alanine transaminase, aspartate transaminase, creatinine, low-density lipoprotein, anti-Gal-8 levels, the prevalence of hypertension, diabetes mellitus and coronary artery disease were recorded. In addition, the expanded disability status scale and disease duration were evaluated in the patient group. Data were presented as mean ± standard deviations. RESULTS: The mean blood anti-galectin-8 value of the patient group was 4.84 ± 4.53 ng/mL, while it was 4.67 ± 3.40 ng/mL in the control group, and the difference in these values was found statistically insignificant (P > .05). Moreover, body mass index, glucose, alanine transaminase, aspartate transaminase, thyroid-stimulating hormone, and low-density lipoprotein levels were also statistically insignificant (P > .05). CONCLUSION: This study examined anti-Gal-8 levels in MS patients. The relationship between MS and galectin-8 and anti-Gal-8 levels in patients needs further clarification. As a result, the study’s results could help elucidate the pathogenesis of MS and give more evidence for diagnosis.
format Online
Article
Text
id pubmed-9829274
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Lippincott Williams & Wilkins
record_format MEDLINE/PubMed
spelling pubmed-98292742023-01-24 Investigation of anti-galectin-8 levels in patients with multiple sclerosis: A consort-clinical study Cinkir, Ufuk Bir, Levent Sinan Tekin, Selma Karagulmez, Ahmet Magrur Avci Cicek, Esin Senol, Hande Medicine (Baltimore) 5300 Galectins are a family of endogenous mammalian lectins involved in pathogen recognition, killing, and facilitating the entry of microbial pathogens and parasites into the host. They are the intermediators that decipher glycan-containing information about the host immune cells and microbial structures to modulate signaling events that cause cellular proliferation, chemotaxis, cytokine secretion, and cell-to-cell communication. They have subgroups that take place in different roles in the immune system. The effect of galectin-8 on multiple sclerosis disease (MS) has been studied in the literature, but the results seemed unclear. In this study, we aimed to determine anti-galectin-8 (anti-Gal-8) levels in MS and their potential use as biomarkers. METHODS: In this experimental study, 45 MS patients diagnosed according to McDonald criteria were included in the patient group. The healthy control group contained 45 people without MS diagnosis and any risk factors. Demographic data, height, weight, body mass index, blood glucose, thyroid-stimulating hormone, alanine transaminase, aspartate transaminase, creatinine, low-density lipoprotein, anti-Gal-8 levels, the prevalence of hypertension, diabetes mellitus and coronary artery disease were recorded. In addition, the expanded disability status scale and disease duration were evaluated in the patient group. Data were presented as mean ± standard deviations. RESULTS: The mean blood anti-galectin-8 value of the patient group was 4.84 ± 4.53 ng/mL, while it was 4.67 ± 3.40 ng/mL in the control group, and the difference in these values was found statistically insignificant (P > .05). Moreover, body mass index, glucose, alanine transaminase, aspartate transaminase, thyroid-stimulating hormone, and low-density lipoprotein levels were also statistically insignificant (P > .05). CONCLUSION: This study examined anti-Gal-8 levels in MS patients. The relationship between MS and galectin-8 and anti-Gal-8 levels in patients needs further clarification. As a result, the study’s results could help elucidate the pathogenesis of MS and give more evidence for diagnosis. Lippincott Williams & Wilkins 2023-01-06 /pmc/articles/PMC9829274/ /pubmed/36607856 http://dx.doi.org/10.1097/MD.0000000000032621 Text en Copyright © 2022 the Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the Creative Commons Attribution License 4.0 (CCBY) (https://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle 5300
Cinkir, Ufuk
Bir, Levent Sinan
Tekin, Selma
Karagulmez, Ahmet Magrur
Avci Cicek, Esin
Senol, Hande
Investigation of anti-galectin-8 levels in patients with multiple sclerosis: A consort-clinical study
title Investigation of anti-galectin-8 levels in patients with multiple sclerosis: A consort-clinical study
title_full Investigation of anti-galectin-8 levels in patients with multiple sclerosis: A consort-clinical study
title_fullStr Investigation of anti-galectin-8 levels in patients with multiple sclerosis: A consort-clinical study
title_full_unstemmed Investigation of anti-galectin-8 levels in patients with multiple sclerosis: A consort-clinical study
title_short Investigation of anti-galectin-8 levels in patients with multiple sclerosis: A consort-clinical study
title_sort investigation of anti-galectin-8 levels in patients with multiple sclerosis: a consort-clinical study
topic 5300
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9829274/
https://www.ncbi.nlm.nih.gov/pubmed/36607856
http://dx.doi.org/10.1097/MD.0000000000032621
work_keys_str_mv AT cinkirufuk investigationofantigalectin8levelsinpatientswithmultiplesclerosisaconsortclinicalstudy
AT birleventsinan investigationofantigalectin8levelsinpatientswithmultiplesclerosisaconsortclinicalstudy
AT tekinselma investigationofantigalectin8levelsinpatientswithmultiplesclerosisaconsortclinicalstudy
AT karagulmezahmetmagrur investigationofantigalectin8levelsinpatientswithmultiplesclerosisaconsortclinicalstudy
AT avcicicekesin investigationofantigalectin8levelsinpatientswithmultiplesclerosisaconsortclinicalstudy
AT senolhande investigationofantigalectin8levelsinpatientswithmultiplesclerosisaconsortclinicalstudy